See how EMET supports preclinical teams focused on experimental design, compound profiling, and execution planning.
Preclinical capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
Design a validation study for our BRCA2 biomarker in triple-negative breast cancer - recommend the assay type, calculate the sample size for 80% power at p<0.05, define the control arms, and flag any confounds we need to account for.
Map the spatial distribution of TIGIT and PD-L1 co-expression across NSCLC tumor sections - identify immune-excluded vs inflamed microenvironments and flag which spatial clusters would be eligible for combination checkpoint blockade.
Given this SMILES, profile my EGFR T790M inhibitor candidate for physicochemical properties, ADMET liabilities, and structural alerts, and compare its drug-likeness to approved EGFR inhibitors.
Analyze our genome-wide CRISPR screen from KRAS G12D pancreatic cancer cells (MAGeCK scores uploaded). Identify the top essential genes, find their synthetic lethal partners in SynLethDB, filter for druggability, and produce a prioritized hit list with existing compounds.
Profile the druggability of PRMT5 as a cancer target - what is its Pharos development level, which inhibitors have published IC50 data, and what are the key ADMET liabilities for the leading scaffolds?
